论文信息 - New pathway for qualification of novel methodologies in the European medicines agency

New pathway for qualification of novel methodologies in the European medicines agency

The European Medicines Agency (EMA) qualification process is a new, voluntary, scientific pathway leading to either a Committee for Medicinal Products for Human Use (CHMP) opinion or a Scientific Advice on innovative methods or drug development tools:

[1] K. Prasse,et al. Microscopic evaluation of veterinary pathology slides. , 1986, Toxicology and applied pharmacology.

[2] M. A. Weinberger. How Valuable is Blind Evaluation in Histopathologic Examinations in Conjunction with Animal Toxicity Studies? , 1979 .

[3] H. Eichler,et al. Factors associated with success of market authorisation applications for pharmaceutical drugs submitted to the European Medicines Agency , 2009, European Journal of Clinical Pharmacology.

[4] Dawn G Goodman,et al. Best Practices Guideline: Toxicologic Histopathology , 2004, Toxicologic pathology.

[5] M. Iatropoulos. Appropriateness of Methods for Slide Evaluation in the Practice of Toxicologic Pathology , 1984, Toxicologic pathology.

[6] K. Pandher,et al. Topic of Histopathology Blinding in Nonclinical Safety Biomarker Qualification Studies , 2010, Toxicologic pathology.